DSPE-PEG2000-Maleimide

DSPE-PEG2000-Maleimide is a phospholipid-PEG conjugate. DSPE-PEG2000-Maleimide utilizes the amphiphilicity of DSPE to insert into the lipid bilayer of liposomes or nanoparticles. DSPE-PEG2000-Maleimide covalently couples to the sulfhydryl (-SH) of ligands (such as antibodies, peptides, or proteins) via thiol-maleimide click chemistry, giving the particles targeting capabilities. DSPE-PEG2000-Maleimide can be used in the researches of breast cancer, lymphoma, and inherited retinal degeneration[1][2][3][4].

Product Specifications

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Liposome

Type

Oligonucleotides

Related Pathways

Metabolic Enzyme/Protease

Field of Research

Cancer; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/dspe-peg2000-maleimide.html

Purity

99.58

Solubility

DMF : 50 mg/mL (ultrasonic) |DMSO : 12.5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CCCCCCCCCCCCCCCCCC(O[C@](COP(OCCNC(OCCOCCNC(CCN1C(C=CC1=O)=O)=O)=O)(O[Na])=O)([H])COC(CCCCCCCCCCCCCCCCC)=O)=O.[n]

Molecular Weight

2000 (average)

Precautions

H302, H315, H319, H335

References & Citations

[1]Nallamothu R, et al. A targeted liposome delivery system for combretastatin A4: formulation optimization through drug loading and in vitro release studies. PDA J Pharm Sci Technol. 2006;60 (3) :144-155.|[2]Gao J, et al. The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes. Biomaterials. 2011;32 (13) :3459-3470. |[3]Ishida T, et al. A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs. FEBS Lett. 1999 Oct 22;460 (1) :129-33.|[4]Herrera-Barrera M, et al. Peptide-guided lipid nanoparticles deliver mRNA to the neural retina of rodents and nonhuman primates. Sci Adv. 2023 Jan 13;9 (2) :eadd4623.